Review



lom612  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress lom612
    Lom612, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lom612/product/MedChemExpress
    Average 94 stars, based on 6 article reviews
    lom612 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    lom612  (MedChemExpress)
    94
    MedChemExpress lom612
    Lom612, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lom612/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    lom612 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    foxo1 activator  (MedChemExpress)
    94
    MedChemExpress foxo1 activator
    ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, <t>FOXO1,</t> p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Foxo1 Activator, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxo1 activator/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    foxo1 activator - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    foxo1 inhibitor  (MedChemExpress)
    94
    MedChemExpress foxo1 inhibitor
    ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, <t>FOXO1,</t> p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Foxo1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxo1 inhibitor/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    foxo1 inhibitor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    lom612  (TargetMol)
    93
    TargetMol lom612
    ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, <t>FOXO1,</t> p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Lom612, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lom612/product/TargetMol
    Average 93 stars, based on 1 article reviews
    lom612 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, FOXO1, p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Journal: The Journal of Clinical Investigation

    Article Title: FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions

    doi: 10.1172/JCI184932

    Figure Lengend Snippet: ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, FOXO1, p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Article Snippet: When specified, 10 μg/mL VISTA agonist antibody (MH5A, BioLegend), 10 μg/mL VISTA antagonist antibody (13F3, Bio X Cell), 100 nM FOXO1 inhibitor (AS1842856, MedChemExpress), or 1 μM FOXO1 activator (LOM612, MedChemExpress) with corresponding isotype control or vehicle (DMSO) was further added to cultures for the indicated times.

    Techniques: Isolation, Staining, Expressing

    ( A – F ) Human peripheral ILC2s (hILC2s) were stimulated with or without rhIL-33 (100 ng/mL). ( B ) Representative plots of VISTA expression levels and corresponding quantification (as MFI). ( C – F ) hILC2s were treated with 5 μg/mL rhVSIG3 and vehicle control. ( C and D ) Representative plots of GATA-3 ( C ) and Ki67 ( D ) expression levels and corresponding quantification (as MFI). ( E ) Cytokine levels in hILC2 supernatant (per 10 3 ILC2s). ( F ) Representative plots of FOXO1 expression levels and corresponding quantification (as MFI) following 1 hour treatment with rhVSIG3. ( G – J ) A total of 2 × 10 5 hILC2s were transferred intravenously into Rag2 –/– GC –/– mice, followed by intranasal challenge with rhIL-33. On days 1 and 3, mice intravenously received 2 mg/kg rhVSIG3 or vehicle. ( H ) Lung resistance in response to elevating doses of methacholine. ( I ) Total number of ILC2s per lung. ( J ) Total number of eosinophils in BAL fluid. Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using either 2-tailed Student’s t test ( B – F , I , and J ) or 1-way ANOVA followed by Tukey’s post hoc test ( H ); * P < 0.05, ** P < 0.01.

    Journal: The Journal of Clinical Investigation

    Article Title: FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions

    doi: 10.1172/JCI184932

    Figure Lengend Snippet: ( A – F ) Human peripheral ILC2s (hILC2s) were stimulated with or without rhIL-33 (100 ng/mL). ( B ) Representative plots of VISTA expression levels and corresponding quantification (as MFI). ( C – F ) hILC2s were treated with 5 μg/mL rhVSIG3 and vehicle control. ( C and D ) Representative plots of GATA-3 ( C ) and Ki67 ( D ) expression levels and corresponding quantification (as MFI). ( E ) Cytokine levels in hILC2 supernatant (per 10 3 ILC2s). ( F ) Representative plots of FOXO1 expression levels and corresponding quantification (as MFI) following 1 hour treatment with rhVSIG3. ( G – J ) A total of 2 × 10 5 hILC2s were transferred intravenously into Rag2 –/– GC –/– mice, followed by intranasal challenge with rhIL-33. On days 1 and 3, mice intravenously received 2 mg/kg rhVSIG3 or vehicle. ( H ) Lung resistance in response to elevating doses of methacholine. ( I ) Total number of ILC2s per lung. ( J ) Total number of eosinophils in BAL fluid. Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using either 2-tailed Student’s t test ( B – F , I , and J ) or 1-way ANOVA followed by Tukey’s post hoc test ( H ); * P < 0.05, ** P < 0.01.

    Article Snippet: When specified, 10 μg/mL VISTA agonist antibody (MH5A, BioLegend), 10 μg/mL VISTA antagonist antibody (13F3, Bio X Cell), 100 nM FOXO1 inhibitor (AS1842856, MedChemExpress), or 1 μM FOXO1 activator (LOM612, MedChemExpress) with corresponding isotype control or vehicle (DMSO) was further added to cultures for the indicated times.

    Techniques: Expressing, Control

    ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, FOXO1, p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Journal: The Journal of Clinical Investigation

    Article Title: FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions

    doi: 10.1172/JCI184932

    Figure Lengend Snippet: ( A ) Overview of VISTA downstream signaling. ( B – E ) Freshly isolated WT and Vsir –/– aILC2s were stained intranuclearly for p-AKT, FOXO1, p65, and p52. Representative histograms of protein expression of p-AKT ( B ), FOXO1 ( C ), p65 ( D ), and p52 ( E ), and corresponding quantifications as MFI. ( F – I ) WT aILC2s were treated with FOXO1 inhibitor or vehicle. ( G and H ) Representative plots of GATA-3 ( G ) and Ki67 ( H ) expression levels and corresponding quantification (as MFI). ( I ) Cytokine levels in cell supernatant (per 10 3 ILC2s). ( J – M ) WT aILC2s were treated with FOXO1 activator or vehicle. ( K and L ) Representative plots of GATA-3 ( K ) and Ki67 ( L ) expression levels and corresponding quantification (as MFI). ( M ) Cytokine levels in cell supernatant (per 10 3 ILC2s). Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using 2-tailed Student’s t test; ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Article Snippet: When specified, 10 μg/mL VISTA agonist antibody (MH5A, BioLegend), 10 μg/mL VISTA antagonist antibody (13F3, Bio X Cell), 100 nM FOXO1 inhibitor (AS1842856, MedChemExpress), or 1 μM FOXO1 activator (LOM612, MedChemExpress) with corresponding isotype control or vehicle (DMSO) was further added to cultures for the indicated times.

    Techniques: Isolation, Staining, Expressing

    ( A – F ) Human peripheral ILC2s (hILC2s) were stimulated with or without rhIL-33 (100 ng/mL). ( B ) Representative plots of VISTA expression levels and corresponding quantification (as MFI). ( C – F ) hILC2s were treated with 5 μg/mL rhVSIG3 and vehicle control. ( C and D ) Representative plots of GATA-3 ( C ) and Ki67 ( D ) expression levels and corresponding quantification (as MFI). ( E ) Cytokine levels in hILC2 supernatant (per 10 3 ILC2s). ( F ) Representative plots of FOXO1 expression levels and corresponding quantification (as MFI) following 1 hour treatment with rhVSIG3. ( G – J ) A total of 2 × 10 5 hILC2s were transferred intravenously into Rag2 –/– GC –/– mice, followed by intranasal challenge with rhIL-33. On days 1 and 3, mice intravenously received 2 mg/kg rhVSIG3 or vehicle. ( H ) Lung resistance in response to elevating doses of methacholine. ( I ) Total number of ILC2s per lung. ( J ) Total number of eosinophils in BAL fluid. Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using either 2-tailed Student’s t test ( B – F , I , and J ) or 1-way ANOVA followed by Tukey’s post hoc test ( H ); * P < 0.05, ** P < 0.01.

    Journal: The Journal of Clinical Investigation

    Article Title: FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions

    doi: 10.1172/JCI184932

    Figure Lengend Snippet: ( A – F ) Human peripheral ILC2s (hILC2s) were stimulated with or without rhIL-33 (100 ng/mL). ( B ) Representative plots of VISTA expression levels and corresponding quantification (as MFI). ( C – F ) hILC2s were treated with 5 μg/mL rhVSIG3 and vehicle control. ( C and D ) Representative plots of GATA-3 ( C ) and Ki67 ( D ) expression levels and corresponding quantification (as MFI). ( E ) Cytokine levels in hILC2 supernatant (per 10 3 ILC2s). ( F ) Representative plots of FOXO1 expression levels and corresponding quantification (as MFI) following 1 hour treatment with rhVSIG3. ( G – J ) A total of 2 × 10 5 hILC2s were transferred intravenously into Rag2 –/– GC –/– mice, followed by intranasal challenge with rhIL-33. On days 1 and 3, mice intravenously received 2 mg/kg rhVSIG3 or vehicle. ( H ) Lung resistance in response to elevating doses of methacholine. ( I ) Total number of ILC2s per lung. ( J ) Total number of eosinophils in BAL fluid. Data are presented as mean + SEM and are representative of at least 2 independent experiments. Statistical significance was assessed using either 2-tailed Student’s t test ( B – F , I , and J ) or 1-way ANOVA followed by Tukey’s post hoc test ( H ); * P < 0.05, ** P < 0.01.

    Article Snippet: When specified, 10 μg/mL VISTA agonist antibody (MH5A, BioLegend), 10 μg/mL VISTA antagonist antibody (13F3, Bio X Cell), 100 nM FOXO1 inhibitor (AS1842856, MedChemExpress), or 1 μM FOXO1 activator (LOM612, MedChemExpress) with corresponding isotype control or vehicle (DMSO) was further added to cultures for the indicated times.

    Techniques: Expressing, Control